Trial Profile
A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma (KEYNOTE-224)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-224
- Sponsors Merck Sharp & Dohme Corp.
- 11 Oct 2023 Status changed from active, no longer recruiting to completed.
- 21 Jun 2023 Planned End Date changed from 30 Dec 2023 to 9 Oct 2023.
- 09 Feb 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.